Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro.

Garige, Mamatha; Ghosh, Susmita; Roelofs, Brian; Rao, V Ashutosh; Sourbier, Carole

Garige, Mamatha; Ghosh, Susmita; Roelofs, Brian; Rao, V Ashutosh; Sourbier, Carole.

Afiliação

Garige M; Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Ghosh S; Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Roelofs B; Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Rao VA; Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Sourbier C; Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Methods Protoc ; 6(2)2023 Mar 24.

Article em En | MEDLINE | ID: mdl-37104015

Palavras-chave

fluorescence; in-cell western; insulin; insulin receptor; potency; tyrosine phosphorylation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Methods Protoc Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google